Utility of a dedicated pediatric cardiac anticoagulation program: the Boston Children's Hospital experience

Jenna M Murray1, Amy Hellinger, Roger Dionne

  • 1Department of Cardiology, Boston Children's Hospital, Boston, USA.

Pediatric Cardiology
|January 10, 2015
PubMed

Insights

A dedicated pediatric cardiac anticoagulation program effectively manages warfarin therapy in children with congenital heart disease. This specialized service improves time in therapeutic range and patient satisfaction, addressing unique challenges in pediatric anticoagulation.

Area of Science:

  • Pediatric Cardiology
  • Pharmacology
  • Clinical Management

Background:

  • Congenital heart disease (CHD) is a leading cause of stroke in children, often requiring anticoagulation.
  • Warfarin therapy in pediatric patients presents unique challenges due to narrow therapeutic index, drug/diet interactions, small size, and specific cardiac conditions.
  • Lack of established guidelines complicates safe and effective anticoagulation management in this vulnerable population.

Purpose of the Study:

  • To describe the development and outcomes of a dedicated pediatric cardiac anticoagulation service.
  • To centralize management of outpatient anticoagulation for pediatric cardiac patients.
  • To establish a disease-specific resource and adapt to evolving anticoagulation trends.

Main Methods:

  • Establishment of a multidisciplinary Cardiac Anticoagulation Monitoring Program (CAMP) at Boston Children's Hospital in 2009.
  • Centralized management by a dedicated team including pediatric cardiology, nurse practitioners, pharmacy, and nutrition.
  • Enrollment of over 240 patients (5 months to 55 years) with various cardiac indications over 5 years.

Main Results:

  • The CAMP service achieved a favorable overall international normalized ratio (INR) time in therapeutic range (TTR) of 67% (81% with a 0.2 margin), showing steady improvement.
  • Common indications included prosthetic valves (34%), Fontan prophylaxis (20%), and atrial arrhythmias (11%).
  • Development of pediatric-specific guidelines for pharmacogenomics, procedural bridging, and novel anticoagulants, alongside high patient/provider satisfaction.

Conclusions:

  • A dedicated pediatric cardiac anticoagulation program provides a safe and effective strategy for standardizing care.
  • Such programs are associated with high patient and provider satisfaction.
  • These specialized services can adapt to emerging trends in anticoagulation therapy for pediatric cardiology patients.

Related Concept Videos